Skip to main content
SpringerLink
Log in

Tapentadol immediate- and extended-release: a guide to its use in acute and chronic pain

  • Clinical Questions & Answers on Drugs
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Table III

References

  1. Noble M, Tregear SJ, Treadwell JR, et al. Long-term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manage 2008 Feb; 35(2): 214–28

    Article  PubMed  Google Scholar 

  2. Avouac J, Gossec L, Dougados M. Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 2007 Aug; 15(8): 957–65

    Article  PubMed  CAS  Google Scholar 

  3. Frampton JE. Tapentadol immediate release: a review of its use in the treatment of moderate to severe pain. Drugs 2010; 70(13): 1719–43

    Article  PubMed  CAS  Google Scholar 

  4. Hartrick CT, Rozek RJ. Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor. CNS Drugs 2011; 25(5): 359–70

    Article  PubMed  CAS  Google Scholar 

  5. Nucynta® (tapentadol) immediate-release oral tablets. US prescribing information. Raritan (NJ): Ortho-McNeil-Janssen Pharmaceuticals, Inc., 2011 Mar

  6. Palexia 50 and 75 mg film-coated tablets: UK summary of product characteristics. Stokenchurch: Grunenthal Ltd, 2011 Mar 28

  7. Palexia SR 50, 100, 150, 200 and 250 mg prolonged-release tablets: UK summary of product characteristics. Stokenchurch: Grunenthal Ltd, 2011 Mar 28

  8. Nucynta® ER (tapentadol) extended-release oral tablets. US prescribing information. Raritan (NJ): Ortho-McNeil-Janssen Pharmaceuticals, Inc., 2011 Aug

  9. Change to the misuse of drugs act 1971: control of tapentadol and amineptine (circular 005/2011). London: Home Office, 2011 Mar 23

  10. Daniels S, Casson E, Stegmann JU, et al. A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. Curr Med Res Opin 2009 Jun; 25(6): 1551–61

    Article  PubMed  CAS  Google Scholar 

  11. Daniels SE, Upmalis D, Okamoto A, et al. A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin 2009 Mar 10; 25(3): 765–76

    Article  PubMed  CAS  Google Scholar 

  12. Stegmann JU, Weber H, Steup A, et al. The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery. Curr Med Res Opin 2008 Nov; 24(11): 3185–96

    Article  PubMed  CAS  Google Scholar 

  13. Hartrick C, Van Hove I, Stegmann JU, et al. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin Ther 2009 Feb; 31(2): 260–71

    Article  PubMed  CAS  Google Scholar 

  14. Hale M, Upmalis D, Okamoto A, et al. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study. Curr Med Res Opin 2009 May; 25(5): 1095–104

    Article  PubMed  CAS  Google Scholar 

  15. Afilalo M, Etropolski MS, Kuperwasser B. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig 2010; 30(8): 489–505

    Article  PubMed  CAS  Google Scholar 

  16. Buynak R, Shapiro DY, Okamoto A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study. Expert Opin Pharmacother 2010; 11(11): 1787–804

    Article  PubMed  CAS  Google Scholar 

  17. Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin 2011; 27(1): 151–62

    Article  PubMed  CAS  Google Scholar 

  18. Lange B, Kuperwasser B, Okamoto A, et al. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther 2010 Jun; 27(6): 381–99

    Article  PubMed  CAS  Google Scholar 

  19. Wild JE, Grond S, Kuperwasser B, et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract 2010 Sep–Oct; 10(5): 416–27

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tapentadol immediate- and extended-release: a guide to its use in acute and chronic pain. Drugs Ther. Perspect 27, 1–6 (2011). https://doi.org/10.2165/11606080-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11606080-000000000-00000

Search

Navigation